Gilead Sciences licences portfolio of HIV antibodies from The Rockefeller University

This article was originally published here

These investigational agents have potential for use in HIV long-acting therapies for treatment and prevention, as well as cure strategies. HIV bNAbs are a class of immunotherapy agents

The post Gilead Sciences licences portfolio of HIV antibodies from The Rockefeller University appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply